Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a sell-the-news reaction, one analyst wrote.